SEC Filing Summary: Form 8-K
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AdventRX Pharmaceuticals, Inc. (not Savara Inc.) on September 4, 2004. The report discloses significant changes in the company's executive leadership and board composition effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Nicholas J. Virca resigned effective September 4, 2004, from his positions as President, Chief Executive Officer, and member of the Board of Directors.
- Appointment: Evan M. Levine, previously Vice Chairman of the Board, Chief Operating Officer, and Secretary, was appointed President and Chief Executive Officer effective September 4, 2004.
- Public Disclosure: The company announced these changes via a press release on September 8, 2004, which is included as an exhibit to this filing.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook statements, or specific risk factors related to the leadership transition. It references the company's Annual Report on Form 10-KSB (filed March 26, 2004) for details regarding Mr. Levine's business experience and related transactions.
Investor Verification Checklist
- Verify the official press release dated September 8, 2004, for the full rationale behind the leadership change.
- Review the Form 10-KSB filed on March 26, 2004, for details on Evan M. Levine's background and any related party transactions.
- Confirm the current status of Nicholas J. Virca's departure and any potential severance arrangements not detailed in this summary.
- Note the discrepancy between the requested company name (Savara Inc.) and the actual registrant (AdventRX Pharmaceuticals, Inc.).